Benedetta Conte

Publicacions destacades

• Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate

  Autors:

  Francesca Poggio; Marco Tagliamento; Marcello Ceppi; M. Bruzzone; Benedetta Conte;

  Piero Fregatti; Kevin Punie; Evandro de Azambuja; Lucia Del Mastro; Matteo Lambertini.

  Referència: Annals Of Oncology 2022.

• Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

  Autors:

  Tomás Pascual; Aranzazu Fernandez-Martinez; Maki Tanioka; Maria Vittoria Dieci; Sonia Pernas;

  (...)

  Laia Paré; Patricia Galvan; Lisa A Carey; Charles M Perou ; Aleix Prat .

  Veure llistat complet d'autors

  Referència: Clinical Cancer Research 2021.

• Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

  Autors:

  Schettini, F; Giuliano, M; De Placido, P; Arpino, G; De Placido, S;

  (...)

  De Laurentiis, M; Pusztai, L; Rimawi, MF; Schiff, R; Generali, D.

  Veure llistat complet d'autors

  Referència: Cancers 2021.

• Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

  Autors:

  Martínez-Sáez, O; Pascual, T; Brasó-Maristany, F; Chic, N; González-Farré, B;

  (...)

  Prat, A; Rodríguez, A; Martínez, A; Faull, I; Odegaard, JI.

  Veure llistat complet d'autors

  Referència: Npj Breast Cancer 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Autors:

  Martínez-Sáez, O; Chic, N; Pascual, T; Adamo, B; Vidal, M;

  (...)

  Muñoz, M; Prat, A; Martínez, D; Galván, P; Martinez, A.

  Veure llistat complet d'autors

  Referència: Breast Cancer Research 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autors:

  Schettini, F; De Placido, S; Pascual, T; Bráso-Maristany, F; Galván, P;

  (...)

  Schiff, R; Veeraraghavan, J; Rimawi, MF; Osborne, CK; Carey, LA.

  Veure llistat complet d'autors

  Referència: Cancer Treatment Reviews 2020.

• Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

  Autors:

  Cattrini C; Bersanelli M; Latocca MM; Conte B; Vallome G;

  Boccardo F .

  Referència: Cancers 2020.

• Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

  Autors:

  Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C;

  (...)

  Miglietta L; Boccardo F; Ceppi M; Del Mastro L; GIM2 Investigators.

  Veure llistat complet d'autors

  Referència: European Journal Of Cancer 2020.

• Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak

  Autors:

  Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B;

  (...)

  Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M .

  Veure llistat complet d'autors

  Referència: European Journal Of Clinical Investigation 2020.